Avalo Therapeutics (AVTX) said Wednesday that Michael Heffernan has been named board chairman, succeeding Garry Neil.
Neil will continue as chief executive officer and board member, the company said.
Heffernan is the founder and chairman of Collegium Pharmaceutical (COLL), where he also previously served as president and CEO, Avalo said.
Avalo shares were more than 3% higher in recent trading.
Price: 8.72, Change: +0.18, Percent Change: +2.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments